|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2.
|
Horner MJ, Ries LAG, Krapcho M, Neyman N,
Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A,
Miller BA, Lewis DR, Eisner MP, Stinchcomb DG and Edwards BK: SEER
Cancer Statistics Review. 1975–2006, National Cancer Institute;
Bethesda, MD: http://seer.cancer.gov/csr/1975_2006/uri,
based on November 2008 SEER data submission, posted to the SEER web
site, 2009.
|
|
3.
|
Cassidy J, Clarke S, Diaz-Rubio E, et al:
Randomized phase III study of capecitabine plus oxaliplatin
compared with fluorouracil/folinic acid plus oxaliplatin as
first-line therapy for metastatic colorectal cancer. J Clin Oncol.
26:2006–2012. 2008. View Article : Google Scholar
|
|
4.
|
Arkenau HT, Arnold D, Cassidy J, et al:
Efficacy of oxaliplatin plus capecitabine or infusional
fluorouracil/leucovorin in patients with metastatic colorectal
cancer: a pooled analysis of randomized trials. J Clin Oncol.
26:5910–5917. 2008. View Article : Google Scholar
|
|
5.
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Saltz LB, Clarke S, Diaz-Rubio E, et al:
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized
phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Van Cutsem E, Kohne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
11.
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab mono-therapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Bokemeyer C, Bondarenko I, Makhson A, et
al: Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
et al: Cetuximab for the treatment of colorectal cancer. N Engl J
Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Van Cutsem E, Peeters M, Siena S, et al:
Open-label phase III trial of panitumumab plus best supportive care
compared with best supportive care alone in patients with
chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol.
25:1658–1664. 2007.
|
|
15.
|
Meyerhardt JA, Zhu AX, Enzinger PC, et al:
Phase II study of capecitabine, oxaliplatin, and erlotinib in
previously treated patients with metastastic colorectal cancer. J
Clin Oncol. 24:1892–1897. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Van Cutsem E, Verslype C, Beale P, et al:
A phase Ib dose-escalation study of erlotinib, capecitabine and
oxaliplatin in metastatic colorectal cancer patients. Ann Oncol.
19:332–339. 2008.PubMed/NCBI
|
|
17.
|
Bianco R, Rosa R, Damiano V, et al:
Vascular endothelial growth factor receptor-1 contributes to
resistance to anti-epidermal growth factor receptor drugs in human
cancer cells. Clin Cancer Res. 14:5069–5080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ciardiello F, Bianco R, Caputo R, et al:
Antitumor activity of ZD6474, a vascular endothelial growth factor
receptor tyrosine kinase inhibitor, in human cancer cells with
acquired resistance to antiepidermal growth factor receptor
therapy. Clin Cancer Res. 10:784–793. 2004. View Article : Google Scholar
|
|
19.
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
20.
|
Tabernero J, van Cutsem E, Diaz-Rubio E,
et al: Phase II trial of cetuximab in combination with
fluorouracil, leucovorin, and oxaliplatin in the first-line
treatment of metastatic colorectal cancer. J Clin Oncol.
25:5225–5232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Townsley CA, Major P, Siu LL, et al: Phase
II study of erlotinib (OSI-774) in patients with metastatic
colorectal cancer. Br J Cancer. 94:1136–1143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hanauske AR, Cassidy J, Sastre J, et al:
Phase 1b dose escalation study of erlotinib in combination with
infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients
with advanced solid tumors. Clin Cancer Res. 13:523–531. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Spigel DR, Hainsworth JD, Burris HA, et
al: Phase II of FOLFOX4, bevacizumab and erlotinib as first-line
therapy in patients with advanced colorectal cancer. In: ASCO
Gastrointestinal Cancer Symposium: abs. 238, 2006.
|
|
24.
|
Meyerhardt JA, Stuart K, Fuchs CS, et al:
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line
therapy for patients with metastatic colorectal cancer. Ann Oncol.
18:1185–1189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Hecht JR, Mitchell E, Chidiac T, et al: A
randomized phase IIIB trial of chemotherapy, bevacizumab, and
panitumumab compared with chemotherapy and bevacizumab alone for
metastatic colorectal cancer. J Clin Oncol. 27:672–680. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Tol J, Koopman M, Cats A, et al:
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
